SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its drug DCCR [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Soleno Therapeutics made false and misleading statements about the safety of its Phase 3 clinical trial for DCCR, particularly concerning issues of excess fluid retention in participants [5]. - The lawsuit alleges that the administration of DCCR posed greater safety risks than disclosed, impacting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million recovery for investors in 2019 [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].